ALNYLAM PHARMACEUTICALS, INC. (ALNY) Quick Ratio
- Quick ratio · latest quarter: Value 2.79×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.79× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $4.22B ÷ $1.51B ≈ 2.79× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 4.22B USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 1.51B USD | Liabilities, Current |
| Cash and equivalents | 1.71B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 1.60B USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 912.74M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 97.11M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.22B | $1.51B | $1.71B | $1.60B | $912.74M | $97.11M | 2.79× |
| 2025-12-31 | $3.69B | $1.47B | $1.66B | $1.25B | $777.57M | $82.72M | 2.51× |
| 2025-09-30 | $3.69B | $1.56B | $1.49B | $1.23B | $964.77M | $75.38M | 2.37× |
| 2025-06-30 | $3.42B | $1.30B | $1.11B | $1.74B | $567.11M | $71.69M | 2.63× |
| 2025-03-31 | $3.04B | $1.08B | $1.02B | $1.61B | $418.04M | $65.58M | 2.83× |
| 2024-12-31 | $3.09B | $1.19B | $966.43M | $1.72B | $405.31M | $78.51M | 2.61× |
| 2024-09-30 | $3.13B | $1.22B | $1.10B | $1.67B | $353.85M | $75.99M | 2.56× |
| 2024-06-30 | $2.92B | $1.06B | $968.49M | $1.65B | $309.48M | $83.98M | 2.77× |
| 2024-03-31 | $2.68B | $941.71M | $681.88M | $1.68B | $321.38M | $93.99M | 2.85× |
| 2023-12-31 | $2.76B | $967.79M | $812.69M | $1.62B | $327.79M | $89.15M | 2.85× |
| 2023-09-30 | $2.72B | $949.78M | $1.03B | $1.36B | $325.44M | $95.77M | 2.87× |
| 2023-06-30 | $2.25B | $788.64M | $657.80M | $1.37B | $220.63M | $100.45M | 2.85× |
| 2023-03-31 | $2.26B | $673.39M | $672.25M | $1.37B | $219.43M | $131.88M | 3.36× |
| 2022-12-31 | $2.40B | $767.91M | $866.39M | $1.30B | $237.96M | $128.96M | 3.13× |
| 2022-09-30 | $2.43B | $772.79M | $1.07B | $1.17B | $184.51M | $115.49M | 3.14× |
| 2022-06-30 | $2.22B | $657.68M | $575.56M | $1.50B | $142.27M | $88.98M | 3.38× |
| 2022-03-31 | $2.36B | $605.96M | $534.08M | $1.67B | $156.53M | $78.52M | 3.90× |
| 2021-12-31 | $2.57B | $695.71M | $819.98M | $1.55B | $198.57M | $86.36M | 3.69× |
| 2021-09-30 | $2.40B | $610.66M | $1.09B | $1.16B | $141.06M | $97.90M | 3.92× |
| 2021-06-30 | $1.99B | $554.65M | $745.77M | $1.10B | $146.59M | $84.36M | 3.60× |
| 2021-03-31 | $1.76B | $494.82M | $379.54M | $1.27B | $110.63M | $73.94M | 3.56× |
| 2020-12-31 | $1.93B | $585.27M | $496.58M | $1.33B | $102.41M | $75.20M | 3.30× |
| 2020-09-30 | $1.86B | $480.24M | $496.70M | $1.28B | $79.12M | $66.94M | 3.86× |
| 2020-06-30 | $1.91B | $384.30M | $580.83M | $1.26B | $69.11M | $77.42M | 4.97× |
| 2020-03-31 | $1.38B | $338.79M | $467.78M | $836.35M | $75.57M | $68.30M | 4.07× |
| 2019-12-31 | $1.57B | $352.59M | $547.18M | $975.02M | $43.01M | $56.35M | 4.44× |
| 2019-09-30 | $1.77B | $352.86M | $923.30M | $797.75M | $48.11M | $54.56M | 5.01× |
| 2019-06-30 | $1.96B | $328.60M | $1.14B | $790.54M | $30.74M | $40.59M | 5.96× |
| 2019-03-31 | $1.28B | $149.16M | $724.96M | $519.58M | $33.80M | $32.00M | 8.57× |
| 2018-12-31 | $1.10B | $179.49M | $420.15M | $662.80M | $18.76M | $24.07M | 6.14× |
| 2018-09-30 | $1.23B | $121.50M | $316.61M | $905.22M | $3.36M | $11.08M | 10.08× |
| 2018-06-30 | (m) | $113.66M | $361.46M | $1.07B | (m) | (m) | (m) |
| 2018-03-31 | (m) | $115.38M | $396.15M | $1.17B | (m) | (m) | (m) |
| 2017-12-31 | (m) | $144.25M | $645.36M | $1.05B | (m) | (m) | (m) |
| 2017-09-30 | (m) | $101.05M | $202.04M | $746.25M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $108.73M | $408.67M | $514.60M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $95.79M | $171.08M | $385.84M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $131.70M | $193.62M | $424.19M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $81.76M | $168.48M | $531.04M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $70.58M | $271.08M | $571.99M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $66.37M | $231.28M | $748.42M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $62.10M | $180.90M | $848.22M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $57.11M | $149.22M | $828.43M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $66.60M | $151.26M | $788.74M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $80.69M | $306.58M | $660.40M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $95.33M | $75.18M | $526.93M | (m) | (m) | (m) |
| 2014-09-30 | (m) | $56.85M | $82.72M | $507.93M | (m) | (m) | (m) |
| 2014-06-30 | (m) | $53.74M | $80.73M | $524.59M | (m) | (m) | (m) |
| 2014-03-31 | (m) | $83.83M | $350.59M | $314.90M | (m) | (m) | (m) |
| 2013-12-31 | (m) | $53.86M | $53.17M | $192.70M | (m) | (m) | (m) |
| 2013-09-30 | (m) | $54.90M | $11.84M | $181.94M | (m) | (m) | (m) |
| 2013-06-30 | (m) | $53.07M | $24.98M | $184.72M | (m) | (m) | (m) |
| 2013-03-31 | (m) | $49.75M | $97.80M | $138.21M | (m) | (m) | (m) |
| 2012-12-31 | (m) | $48.34M | $51.41M | $71.41M | (m) | (m) | (m) |
| 2012-09-30 | (m) | $54.76M | $75.84M | $152.50M | (m) | (m) | (m) |
| 2012-06-30 | (m) | $57.06M | $48.27M | $180.75M | (m) | (m) | (m) |
| 2012-03-31 | (m) | $66.64M | $61.74M | $137.36M | (m) | (m) | (m) |
| 2011-12-31 | (m) | $80.99M | $70.23M | $76.17M | (m) | (m) | (m) |
| 2011-09-30 | (m) | $93.93M | $74.34M | $98.69M | (m) | (m) | (m) |
| 2011-06-30 | (m) | $100.53M | $67.11M | $150.84M | (m) | (m) | (m) |
| 2011-03-31 | (m) | $99.34M | $90.59M | $154.05M | (m) | (m) | (m) |
| 2010-12-31 | (m) | $102.05M | $74.60M | $158.53M | (m) | (m) | (m) |
| 2010-09-30 | (m) | $99.43M | $46.88M | $184.49M | (m) | (m) | (m) |
| 2010-06-30 | (m) | $102.03M | $66.18M | $193.01M | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | $114.95M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $110.73M | $137.47M | $143.93M | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | $98.09M | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | $147.87M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $191.79M | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $105.16M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |